Determine the necessary mass, volume, or concentration for preparing a solution.
HAMI 3379 - ≥95% , CAS No.1245653-57-9
AVAILABLE TO ORDER
GRADE & PURITY ≥95%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
≥95% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
HAMI 3379 is a potent and selective CysLT 2 receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation
In Vitro
In a CysLT 2 receptor reporter cell line, HAMI3379 antagonizes leukotriene D 4 - (LTD 4 -) and leukotriene C 4 - (LTC 4 -) induced intracellular calcium mobilization with IC 50 values of 3.8 nM and 4.4 nM respectively. HAMI3379 exhibits very low potency on a recombinant CysLT 1 receptor cell line (IC 50 >10000 nM). HAMI3379 does not exhibit any agonistic activity on both CysLT receptor cell lines. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
HAMI 3379 (0.025-0.4 mg/kg; ip) with 0.1-0.4 mg/kg significantly reduces the infarct volume and percentage increase in the ischemic/contralateral hemispheric ratio. HAMI3379 (0.1 mg/kg; ip) administered at 0 and 1 h after reperfusion reduces infarct volume, attenuated brain edema, reduced neurological score, and increased holdingangle. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats (250-300 g) after MCAODosage: 0.025, 0.05, 0.1, 0.2, 0.4 mg/kg Administration: IP Result: Significantly reduced the infarct volume and percentage increase inthe ischemic/contralateral hemispheric ratio (an index ofbrain edema) with 0.1-0.4 mg/kg. Significantly reduced the neurological deficit score.
Form:Solid
IC50& Target:CysLT 2
Specifications
Specifications & Purity
≥95%
Biochemical and Physiological Mechanisms
HAMI 3379 is a potent and selective CysLT 2 receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation.
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
ANTAGONIST
Purity
≥95%
Names and Identifiers
| Molecular Weight | 595.72 |
|---|
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.